Experience during the COVID-19 pandemic should help to guide companies and regulators towards new ways of approaching clinical trials, with more use of novel study design, remote site monitoring, and wider use of digital technology, industry speakers said during a webinar this week organized by the European pharma industry body EFPIA.
Representatives of pharmaceutical companies and the European Commission said experience during the pandemic might also help to spur greater harmonization...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?